Vantage Investment Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Vantage Investment Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-3,000	Closed	-$7K	–	770
2018 Q1	$7K	Hold	3,000	–	–	﹤0.01%	614
2017 Q4	$12K	Hold	3,000	–	–	﹤0.01%	539
2017 Q3	$8K	Hold	3,000	–	–	﹤0.01%	591
2017 Q2	$8K	Hold	3,000	–	–	﹤0.01%	586
2017 Q1	$6K	Hold	3,000	–	–	﹤0.01%	609
2016 Q4	$3K	Hold	3,000	–	–	﹤0.01%	672
2016 Q3	$3K	Hold	3,000	–	–	﹤0.01%	650
2016 Q2	$2K	Hold	3,000	–	–	﹤0.01%	720
2016 Q1	$4K	Hold	3,000	–	–	﹤0.01%	641
2015 Q4	$7K	Hold	3,000	–	–	﹤0.01%	553
2015 Q3	$9K	Hold	3,000	–	–	0.01%	512
2015 Q2	$12K	Sell	3,000 -3,000	-50%	-$12K	0.01%	442
2015 Q1	$26K	Buy	6,000 +3,000	+100%	+$10.8K	0.01%	443
2014 Q4	$9K	Hold	3,000	–	–	0.01%	515
2014 Q3	$10K	Hold	3,000	–	–	0.01%	472
2014 Q2	$8K	Hold	3,000	–	–	﹤0.01%	498
2014 Q1	$7K	Hold	3,000	–	–	﹤0.01%	475
2013 Q4	$6K	Buy	+3,000	New	+$6.06K	﹤0.01%	472

Other funds holding CPRX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vantage Investment Advisors's CPRX Position: Q2 2018 in Review

Vantage Investment Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q2 2018, closing a stake of 3,000 shares — an estimated $7K sold.

Vantage Investment Advisors first reported a position in CPRX in Q4 2013 and held it in 18 quarters. The position peaked at $26K in Q1 2015. 99 funds tracked by Wall St. Rank hold CPRX as of Q2 2018.

Vantage Investment Advisors reported no remaining Catalyst Pharmaceutical position as of Q2 2018 after selling out during the quarter.
Vantage Investment Advisors sold 3,000 Catalyst Pharmaceutical shares in Q2 2018, an estimated $7K.
Vantage Investment Advisors first reported a position in Catalyst Pharmaceutical in Q4 2013 and held it in 18 quarters.
Vantage Investment Advisors's Catalyst Pharmaceutical position peaked at $26K in Q1 2015.
99 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2018.

Based on Vantage Investment Advisors's 13F filing for Q2 2018, filed 13 Aug 2018.